Please ensure Javascript is enabled for purposes of website accessibility

What's Behind Aerie Pharmaceuticals' 12.9% Rally Today

By Todd Campbell - Sep 20, 2016 at 12:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares are spiking after Wall Street analysts issue "buy" ratings.

Image source: Getty Images.

What happened

After reporting positive phase 3 trial results for its glaucoma drug Roclatan last week, optimism at Wall Street research firms is helping to propel shares in Aerie Pharmaceuticals (AERI 3.18%) 12.9% higher today at 12:30 p.m. EDT today.

So what

Phase 3 results for Roclatan, the company's next-generation therapy for reducing in intraocular eye pressure (IOP) in glaucoma patients, could position it to win away significant share in the $2.5 billion market for glaucoma treatment. 

Image source: Aerie Pharmaceuticals.

In the study, Roclatan, which combines the widely used glaucoma drug, latanoprost, a prostaglandin analogue (PGA), with Aerie Pharmaceuticals' first-generation IOP drug, Rhopressa, delivered a 1 to 3 mmHg improvement versus the use of latanoprost or Rhopressa alone.

If a second phase 3 trial evaluating Roclatan reads out similarly, then it should allow Aerie Pharmaceuticals to file for Food and Drug Administration approval next year. 

The company also expects to receive a go/no-go decision from the FDA on its once-daily Rhopressa in 2017. If approved, Rhopressa could be used as an adjunct therapy to PGA's like latanoprost instead of beta blockers. In trials, Rhopressa's efficacy was similar to twice-daily beta blockers, which suggests Rhopressa's easier dosing could allow it to capture up to 14% of the U.S. glaucoma market.

As the potential for these drugs is being modeled into Wall Street's projections, it is increasingly bullish about Aerie Pharmaceuticals stock. On Friday, Raymond James initiated coverage on the company with a strong buy and a price target of $48. Today, H.C. Wainwright initiated coverage with a "buy" rating and a target price of $66.

Now what

In preparation for costly launches, Aerie Pharmaceuticals just completed stock offerings that add $125 million, minus fees, to its balance sheet.

The company's firm financial footing and an opportunity to serve a market that's growing because of aging baby boomers makes this a very intriguing stock. However, investors should remember that there's no guarantee that Roclatan's second trial will pan out or that Rhopressa will net a FDA green light. Nevertheless, I think that the risk/reward for this stock is pretty good, so I'll be looking to buy it in my portfolio.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aerie Pharmaceuticals, Inc. Stock Quote
Aerie Pharmaceuticals, Inc.
AERI
$7.14 (3.18%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
327%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.